missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ KIAA0101 Polyclonal Antibody
Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA565485
This item is not returnable.
View return policy
Description
Immunogen sequence: VRTKADSVPGT YRKVVAARAP RKVLGSSTSA TNSTSVSSRK Highest antigen sequence identity to the following orthologs - mouse 76%, rat 78%.
PCNA-binding protein that acts as a regulator of DNA repair during DNA replication. Following DNA damage, the interaction with PCNA is disrupted, facilitating the interaction between monoubiquitinated PCNA and the translesion DNA synthesis DNA polymerase eta (POLH) at stalled replisomes, facilitating the bypass of replication-fork-blocking lesions. Also acts as a regulator of centrosome number.
Specifications
| KIAA0101 | |
| Polyclonal | |
| Unconjugated | |
| PCLAF | |
| 2810417H13Rik; AA409629; HCV NS5A-transactivated protein 9; HCV NS5A-transactivated protein 9 homolog; hepatitis C virus NS5A-transactivated protein 9; hypothetical protein LOC540737; KIAA0101; L5; mKIAA0101; NS5A (hepatitis C virus) transactivated protein 9; Ns5apt9; NS5ATP9; OEATC; OEATC1; OEATC-1; overexpressed in anaplastic thyroid carcinoma 1; p15(PAF); p15/PAF; p15PAF; PAF; PAF15; Pclaf; PCNA clamp associated factor; PCNA-associated factor; PCNA-associated factor of 15 kDa; PCNA-associated factor-like protein; PCNA-clamp-associated factor; RIKEN cDNA 2810417H13 gene | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 9768 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Immunocytochemistry | |
| 0.05 mg/mL | |
| PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
| Q15004 | |
| PCLAF | |
| Recombinant Human KIAA0101. Recombinant protein control fragment (Product #RP-106159). | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction